Myeloid sarcoma predicts superior outcome in pediatric AML; can cytogenetics solve the puzzle? R Pramanik, A Tyagi, A Chopra, A Kumar, S Vishnubhatla, S Bakhshi Clinical Lymphoma Myeloma and Leukemia 18 (6), e249-e254, 2018 | 21 | 2018 |
Adiponectin correlates with obesity: A study of 159 childhood acute leukemia survivors from India R Srivastava, A Batra, A Tyagi, D Dhawan, L Ramakrishnan, S Bakhshi Indian journal of cancer 52 (2), 195-197, 2015 | 17 | 2015 |
Cytogenetic profiles of 472 Indian children with acute myeloid leukemia A Tyagi, R Pramanik, S Chaudhary, A Chopra, S Bakhshi Indian Pediatrics 55, 469-473, 2018 | 16 | 2018 |
Evidence supporting a role for the immune checkpoint protein B7-H3 in NK cell-mediated cytotoxicity against AML A Tyagi, S Ly, F El-Dana, B Yuan, A Jaggupilli, S Grimm, M Konopleva, ... Blood, The Journal of the American Society of Hematology 139 (18), 2782-2796, 2022 | 14 | 2022 |
Pattern of mitochondrial D-loop variations and their relation with mitochondrial encoded genes in pediatric acute myeloid leukemia A Tyagi, R Pramanik, S Vishnubhatla, S Ali, R Bakhshi, A Chopra, A Singh, ... Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis 810, 13-18, 2018 | 13 | 2018 |
Evaluation of vascular endothelial growth factor (VEGF) and thrombospondin-1 as biomarkers of metronomic chemotherapy in progressive pediatric solid malignancies R Pramanik, A Tyagi, S Agarwala, S Vishnubhatla, D Dhawan, S Bakhshi Indian Pediatrics 57, 508-511, 2020 | 10 | 2020 |
Expression of mitochondrial genes predicts survival in pediatric acute myeloid leukemia A Tyagi, R Pramanik, R Bakhshi, A Singh, S Vishnubhatla, S Bakhshi International Journal of Hematology 110, 205-212, 2019 | 8 | 2019 |
Prognostic impact of mitochondrial DNA D-loop variations in pediatric acute myeloid leukemia A Tyagi, R Pramanik, S Vishnubhatla, R Bakhshi, S Bakhshi Oncotarget 10 (13), 1334, 2019 | 8 | 2019 |
Dysregulation of miRNA expression and their prognostic significance in paediatric cytogenetically normal acute myeloid leukaemia V Gaur, S Chaudhary, A Tyagi, S Agarwal, SK Sharawat, S Sarkar, ... British Journal of Haematology 188 (6), e90-e94, 2020 | 6 | 2020 |
AML-327 Novel Anti–B7-H3 Blocking Antibody Enhances NK Cell–Mediated Cytotoxicity and Improves Outcomes in AML-Bearing Mice A Tyagi, S Ly, F El-Dana, B Yuan, A Jaggupilli, S Grimm, L Bover, ... Clinical Lymphoma Myeloma and Leukemia 22, S236, 2022 | 2 | 2022 |
Apoptosis: A biomarker of high‐risk phenotype in pediatric acute myeloid leukemia? A Tyagi, R Pramanik, R Bakhshi, S Vishnubhatla, S Bakhshi International Journal of Laboratory Hematology 41 (1), 141-147, 2019 | 2 | 2019 |
Targeting Myeloid Epithelial Tyrosine Kinase (MERTK) Receptor in Acute Myeloid Leukemia Using a Novel Antibody Drug Conjugate, Rgx-019-MMAE A Tyagi, M Siddiqui, I Kurth, S Takeda, A Eckstrom, J Borgman, A Maiti, ... Blood 142, 5955, 2023 | 1 | 2023 |
FT538, iPSC-Derived NK Cells Are Potent Inducers of Apoptosis in AML Cells and Their Effect Is Synergistic in Combination with Approved Therapeutic Strategies A Eckstrom, A Tyagi, M Siddiqui, S Mahmood, L Wong, BB Valamehr, ... Blood 142, 4817, 2023 | 1 | 2023 |
Abstract P2-20-06: Anti-B7-H3 Antibody (T-1A5) Blocks Immunomodulatory Function of B7-H3 and Enhances NK and T Cell–Mediated Cytotoxicity against Breast Cancer Cells V Anand, A Tyagi, VL Battula Cancer Research 83 (5_Supplement), P2-20-06-P2-20-06, 2023 | 1 | 2023 |
Anti-B7-H3 Antibody (T-1A5) Blocks Immunomodulatory Function of B7-H3 and Enhances NK Cell-Mediated Cytotoxicity Against Acute Myeloid Leukemia Cells A Tyagi, S Ly, F El-Dana, B Yuan, S Grimm, HJ Bühring, VL Battula Blood 138, 3336, 2021 | 1 | 2021 |
Targeting myeloid epithelial tyrosine kinase (MERTK) receptor in acute myeloid leukemia using a novel antibody-drug conjugate, RGX-019-MMAE A Tyagi, M Siddiqui, I Kurth, S Takeda, A Eckstrom, J Borgman, A Maiti, ... Cancer Research 84 (6_Supplement), 6341-6341, 2024 | | 2024 |
GD3 synthase (ST8SIA1) is a key immunomodulator in GD2+ breast cancer cells B Oderinde, V Anand, M Siddiqui, A Tyagi, B Jenny, VL Battula Cancer Research 84 (6_Supplement), 2672-2672, 2024 | | 2024 |
TP-0184 inhibits FLT3/ACVR1 to overcome FLT3 inhibitor resistance and hinder AML growth synergistically with venetoclax A Tyagi, A Jaggupilli, S Ly, B Yuan, F El-Dana, VL Hegde, V Anand, ... Leukemia 38 (1), 82-95, 2024 | | 2024 |
Abstract B122: 2 for 1: Targeting tumor-associated macrophages and cancer cells with a novel MERTK-targeting antibody-drug conjugate (ADC) S Takeda, PC Lo, D Schefer, M Siddiqui, A Tyagi, VL Battula, A Maiti, ... Molecular Cancer Therapeutics 22 (12_Supplement), B122-B122, 2023 | | 2023 |
ERK1/2 Inhibition Overcomes Resistance to Venetoclax in AML By Inhibiting Drp1 Dependent Mitochondrial Fission P Sharma, LB Ostermann, S Piya, B Ke, N Baran, A Tyagi, M Muftuoglu, ... Blood 142 (Supplement 1), 412-412, 2023 | | 2023 |